Fmr LLC Increases Position in Catalent, Inc. (NYSE:CTLT)

FMR LLC grew its stake in shares of Catalent, Inc. (NYSE:CTLT - Free Report) by 4.8% during the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 265,369 shares of the company's stock after acquiring an additional 12,241 shares during the quarter. FMR LLC owned about 0.15% of Catalent worth $16,073,000 as of its most recent SEC filing.

Several other hedge funds have also recently made changes to their positions in the stock. Nisa Investment Advisors LLC lifted its holdings in Catalent by 1.7% during the second quarter. Nisa Investment Advisors LLC now owns 11,013 shares of the company's stock valued at $619,000 after purchasing an additional 185 shares in the last quarter. Sumitomo Mitsui DS Asset Management Company Ltd grew its position in shares of Catalent by 1.1% during the third quarter. Sumitomo Mitsui DS Asset Management Company Ltd now owns 19,458 shares of the company's stock valued at $1,179,000 after purchasing an additional 220 shares in the last quarter. Crossmark Global Holdings Inc. lifted its position in shares of Catalent by 2.6% in the third quarter. Crossmark Global Holdings Inc. now owns 9,133 shares of the company's stock worth $553,000 after buying an additional 229 shares in the last quarter. Vanguard Personalized Indexing Management LLC grew its holdings in Catalent by 3.8% during the 2nd quarter. Vanguard Personalized Indexing Management LLC now owns 7,688 shares of the company's stock valued at $432,000 after buying an additional 278 shares in the last quarter. Finally, GAMMA Investing LLC boosted its position in shares of Catalent by 26.9% during the 3rd quarter. GAMMA Investing LLC now owns 1,310 shares of the company's stock valued at $79,000 after acquiring an additional 278 shares during the last quarter.

Insiders Place Their Bets

In related news, insider David Mcerlane sold 1,994 shares of the company's stock in a transaction that occurred on Thursday, September 26th. The stock was sold at an average price of $59.97, for a total value of $119,580.18. Following the transaction, the insider now directly owns 36,304 shares in the company, valued at approximately $2,177,150.88. This represents a 5.21 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director Michelle R. Ryan sold 2,800 shares of the firm's stock in a transaction dated Monday, November 11th. The stock was sold at an average price of $59.70, for a total value of $167,160.00. Following the sale, the director now directly owns 10,835 shares of the company's stock, valued at $646,849.50. The trade was a 20.54 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 5,114 shares of company stock valued at $305,931 in the last 90 days. 0.31% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

Several brokerages have issued reports on CTLT. StockNews.com downgraded shares of Catalent from a "hold" rating to a "sell" rating in a research note on Tuesday. Robert W. Baird reissued a "neutral" rating and set a $63.50 price target on shares of Catalent in a research report on Tuesday, September 24th. William Blair restated a "market perform" rating on shares of Catalent in a report on Tuesday, September 3rd. Finally, Baird R W lowered shares of Catalent from a "strong-buy" rating to a "hold" rating in a research note on Tuesday, September 24th. One analyst has rated the stock with a sell rating and seven have assigned a hold rating to the company's stock. Based on data from MarketBeat, the stock has a consensus rating of "Hold" and a consensus price target of $63.40.

Catalent Stock Performance

Shares of CTLT traded up $0.99 during trading hours on Wednesday, hitting $63.23. The stock had a trading volume of 7,816,165 shares, compared to its average volume of 2,076,811. The firm has a 50-day moving average price of $60.15 and a 200 day moving average price of $58.85. Catalent, Inc. has a fifty-two week low of $36.74 and a fifty-two week high of $63.25. The firm has a market capitalization of $11.48 billion, a price-to-earnings ratio of -27.98, a PEG ratio of 2.46 and a beta of 1.15. The company has a debt-to-equity ratio of 1.38, a quick ratio of 1.96 and a current ratio of 2.51.

Catalent (NYSE:CTLT - Get Free Report) last announced its earnings results on Tuesday, November 5th. The company reported ($0.13) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.05 by ($0.18). The business had revenue of $1.02 billion for the quarter, compared to analysts' expectations of $1.06 billion. Catalent had a negative net margin of 9.28% and a negative return on equity of 0.66%. The company's quarterly revenue was up 4.2% on a year-over-year basis. During the same quarter last year, the business earned ($0.10) EPS. As a group, research analysts anticipate that Catalent, Inc. will post 0.84 EPS for the current year.

Catalent Company Profile

Catalent, Inc, together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates in two segments, Biologics, and Pharma and Consumer Health. The Biologics segment provides formulation, development, and manufacturing for biologic proteins, cell gene, and other nucleic acid therapies; pDNA, iPSCs, oncolytic viruses, and vaccines; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges; and analytical development and testing services for large molecules.